The Recall Desk

Manufacturer

Attix Pharmaceuticals

470 recalls in our database name Attix Pharmaceuticals as the manufacturing or recalling firm.

What the numbers show

Total
470
Critical
0
Severe
378
Most recent
2015-04-29

Of the 470 recalls from Attix Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 378 (80%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

426–450 of 470

  • HighFDA (Drugs)·D-767-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lodenafil Carbonate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Lodenafil Carbonate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Lodenafil Carbonate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-848-2015·2015-04-29

    Attix Pharmaceuticals Recalls Polidocanol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Polidocanol (Industrial Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Polidocanol (Industrial Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-938-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tranexamic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tranexamic Acid active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tranexamic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-679-2015·2015-04-29

    Flumazenil API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Flumazenil active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flumazenil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-585-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cilostazol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling cilostazol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cilostazol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-780-2015·2015-04-29

    Attix Pharmaceuticals Recalls Metaxalone API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Metaxalone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Metaxalone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-863-2015·2015-04-29

    Attix Pharmaceuticals Recalls Procainamide HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Procainamide HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Procainamide HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-695-2015·2015-04-29

    Attix Pharmaceuticals Recalls Furosemide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling furosemide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Furosemide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-652-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Estradiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-786-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methotrexate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methotrexate USP active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methotrexate USP active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-545-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bismuth Subcarbonate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bismuth Subcarbonate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Bismuth Subcarbonate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-524-2015·2015-04-29

    Attix Pharmaceuticals Recalls Artemether Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Artemether active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Artemether active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-769-2015·2015-04-29

    Attix Pharmaceuticals Recalls Loratadine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Loratadine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Loratadine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-550-2015·2015-04-29

    Attix Pharmaceuticals Recalls Budesonide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling budesonide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Budesonide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-809-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mupirocin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mupirocin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mupirocin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-869-2015·2015-04-29

    Progesterone API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling progesterone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Progesterone Ultra-Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-846-2015·2015-04-29

    Attix Pharmaceuticals Recalls Podophyllum Resin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Podophyllum Resin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Podophyllum Resin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-876-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rebamipide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Rebamipide API distributed between January 2012 and February 2015 due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Rebamipide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-866-2015·2015-04-29

    Attix Pharmaceuticals Recalls Procarbazine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Procarbazine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Procarbazine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-724-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxyzine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxyzine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hydroxyzine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-609-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dacarbazine Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Dacarbazine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dacarbazine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-751-2015·2015-04-29

    Attix Pharmaceuticals Recalls Letrazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Letrazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Letrazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-703-2015·2015-04-29

    Attix Pharmaceuticals Recalls Heparin Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Heparin Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Heparin Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-693-2015·2015-04-29

    Attix Pharmaceuticals Recalls Fulvestrant API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Fulvestrant active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Fulvestrant active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-784-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methocarbamol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling methocarbamol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methocarbamol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide